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INTRODUCTION 
 Discoid lupus erythematosus  is a benign disorder of the skin 
characterised by well defined, erythematous atrophic plaques covered by a 
prominent, adherent scale that extends into the orifices of dilated hair follicles. 
The disease affects twice as many females as males. 
 The salient histopathological features of classic DLE lesion are 
hyperkeratosis with follicular plugging, liquefaction degeneration of basal cell 
layer of epidermis, degenerative changes in the connective tissue and patchy 
dermal lymphocytic infiltrate  around the appendages. Immunohistology shows 
presence of immunoglobulins IgG, IgA, IgM and complement at the dermo-
epidermal junction  in the skin lesions.    
   The majority of researchers consider DLE to be part of a spectrum of 
the lupus erythematosus diseases (LE). Accordingly, the clinical expression of 
LE varies from DLE, a benign and strictly cutaneous form, to a systemic form 
with an unfavorable prognosis, known as Systemic Lupus Erythematosus 
(SLE). The risk of developing overt SLE is only approximately 6.5%. The risk 
is higher in patients with Disseminated DLE (22%) than in DLE confined to the 
head and neck (1.2%) . 
 
REVIEW OF LITERATURE 
 Hippocrates, Rogerius, Paracelsus, Manardi, Amatus Lusitanus, Sennert 
are some of the early renowned physicians who have described “Lupus” which 
is derived from the Latin word which means “Wolf” 1 depicting its nature of 
destruction.  
 Lupus Erythematosus (LE) was identified only as a cutaneous disease 
until a century ago. At the beginning of the last century, blood vessels and 
connective tissues distributed throughout the body came to be implicated in the 
pathogenesis which led to the concept of “multisystem malady”2 .In 1942, 
Klemperer et al were struck by many morphological features that were common 
to diseases such as lupus erythematosus, scleroderma, dermatomyositis, 
rheumatoid arthritis, acute rheumatic fever and polyarthritis nodosa and 
classified them as “collagen disease” or “collagenosis” 1  . 
HISTORICAL BACKGROUND: 
 In 1826 Rayer1 described Lupus Erythematosus as “Flexus Sebaceui”. In 
1828 Biett3 described the condition as “Erythema Centrifuge”. In 1845 Hebra1 
described it as “Seborrhea Congestiva” in which the simile “Butterfly Rash” 
was used for the first time. In 1851, Cazenave first used the term “lupus 
erythemateaux” meaning “red wolf” in order to distinguish this disease from 
lupus vulgaris4.In 1875, Kaposi differentiated LE into two forms namely the 
discoid form and lupus erythematosus disseminatus3. 
 In 1963, Edmund Dubois was among the first to use the “Spectrum” 
analogy for LE, emphasizing that this illness represented a disease continuum 
extending from the localized DLE at the more benign pole to fully expressed 
SLE at the more severely affected pole5. Dubois’ spectrum concept influenced 
Jim Gilliam’s thinking concerning the classification of Cutaneous LE.  
DEFINITION: 
 Discoid Lupus Erythematosus is a benign disorder of the skin 
characterized by well demarcated, erythematous, slightly infiltrated, “discoid “ 
plaques that often shows adherent thick scales that extend into orifices of dilated 
hair follicle. The lesion heals with atrophy, scarring and pigmentary changes. 
The term “DLE” has been used synonymously with the term Cutaneous Lupus 
Erythematosus. 
 N.Gilliam divides the cutaneous manifestation of LE into those that 
shows characteristic histologic changes of LE (LE-Specific skin disease) and 
those that are not histopathologically distinct for LE and / or may be seen as 
feature of another disease process (LE-Non specific skin disease). 
 The term Cutaneous LE is often used synonymously with LE-specific 
skin disease as an umbrella designation for the three major categories of LE-
specific skin disease: Acute Cutaneous Lupus Erythematosus (ACLE), Subacute 
Cutaneous Lupus Erythematosus (SCLE), and Chronic Cutaneous Lupus 
Erythematosus (CCLE). DLE lesions are the most common form of CCLE. 
TYPES OF DLE: 
          Discoid Lupus Erythematosus is classified clinically into the following 
types6 . 
  1.Classic Discoid LE (DLE) 
   a. Localised DLE 
   b. Generalised DLE 
  2.Hypertrophic / Verrucous DLE 
  3.Lupus profundus / Lupus panniculitis 
  4.Mucosal DLE 
   a.Oral DLE 
   b.Conjunctival DLE 
  5.Lupus tumidus 
  6.Chilblain LE 
  7.Lichenoid DLE (LE / Lichen planus overlap) 
 EPIDEMIOLOGY OF DLE: 
  DLE generally affects twice as many females as males, with a peak age 
of onset in the fourth decades in female and slightly later in males7. It is only 
half as frequent in black people8. In a series of 1045 cases, 3% began under 15 
years of age and 2.5% at over 70 years9. A family history was found in 4% of 
patients in one series10. 
AETIOLOGY AND PATHOGENESIS: 
 The causes and pathogenic mechanism responsible are not fully 
understood. An attractive contemporary model describes four theoretical 
temporally sequential phases that are prerequisite for the clinical expression of 
this disease. These phases are inheritance of susceptibility genes, induction of 
autoimmunity, expansion of autoimmune processes and immunological injury11. 
 Genetic susceptibility is probably related to genes that decrease the 
threshold for self-reactivity and allow a sustained immune response after the 
first response or the type and extent of end-organ damage12. The autoimmune 
induction phase refers to the development of self-reactive T cells that 
demonstrate loss of self-tolerance13. Mechanisms of induction may include 
molecular mimicry induced by infectious antigens, abnormal expression of 
human leucocyte antigen DR, malfunction of thymic or peripheral tolerance, 
and presentation of cryptic peptides during apoptosis. The expansion phase 
involves the progressive development of abnormal autoimmune clonal 
expansion of B and T cells that have self-recognition capabilities. The final 
injury phase results in clinical disease and is likely related to autoantibodies and 
immune complexes causing tissue damage. Mechanisms likely include direct 
cell death, activation of the complement system, opsonisation and the inhibiting 
function of target molecule13. 
 
Genetic Factors: 
 Genetic factors, including somatic mutation are implicated in the 
pathogenesis of the disease. Positive associations with HLA-B7, -B8, -Cw7, -
DR2, -DR3 and DQW1 are reported14. The relative risk is increased with certain 
combinations of antigens –HLA-CW7, -DR3 and -DQW1 and for HLA-B7, -
CW7 and –DR3. The extended haplotype –HLA*01, B*08, DRB1*0301- is 
associated with both SCLE and DLE, and the A*03, B*07, DRB1*15 haplotype 
has been associated with DLE lesions14 . 
 
Environmental Factors: 
 Genetic predisposition for a lupus diasthesis does not, in itself, produce 
disease. Rather , it appears that induction of autoimmunity in such patients is 
triggered by some inciting event, likely an environmental exposure. 
 The onset of lesions may be precipitated by a variety of factors. These 
include trauma15 (11%), mental stress (12%), sunburn (5%), infection (3%), 
exposure to cold (2%), pregnancy (1%), exposure to     x-rays, diathermy, 
chemical burns, PUVA therapy, laser therapy and drugs16 (e.g. Isoniazid, 
Penicillamine, Griseofulvin, Dapsone). 
 Patients with the primary antiphospholipid antibody syndrome may also 
develop DLE17. The findings of antibodies to reovirus RNA in 42% of patients 
suggest that viruses may have a role in DLE18. 
 
HISTOPATHOLOGY: 
 In most instances of discoid lesions, diagnosis of lupus erythematosus is 
possible on the basis of a combination of histologic findings. The various 
clinical types of LE shows an essentially similar histological picture. 
 Changes may be apparent at all levels of the skin, but all need not be 
present in every case. The findings are summarized below. 
• Stratum corneum: Hyperkeratosis with follicular plugging. 
• Thinning and flattening of the stratum malpighii, hydropic degeneration 
of basal cells, dyskeratosis and squamatisation of basilar keratinocytes. 
• Basement membrane: thickening and tortuosity 
• Stroma: a predominantly lymphocytic infiltrate arranged along the dermal 
– epidermal junction, around hair follicle and other appendages and in an 
interstitial pattern; Interstitial mucin deposition; edema, vasodilatation, 
and slight extravasations of erythrocytes. 
• Pilosebaceous atrophy is a characteristic feature. 
• Subcutaneous:  Slight extension of inflammatory infiltrate may be 
present.  
The presence of at least two of the following three features is essential to 
the histological diagnosis of LE19. 
1. Liquefaction degeneration of the basal layer of the epidermis. 
2. Degenerative changes in the connective tissue, consisting of 
hyalinization, oedema and fibrinoid change, most marked immediately 
below the epidermis. 
3. A patchy dermal lymphocytic infiltrate with a few plasma cells and 
histiocytes, particularly around the appendages, which may be atrophic 
 
Hypertrophic / Verrucous Lupus Erythematosus 
Histologically, the epidermis shows hyperkeratosis and papillomatosis.  
Large number of dyskeratotic keratinocytes are usually noted in the lower 
portion of the epidermis associated with a band-like mononuclear infiltrate 
along the dermoepidermal junction.  A second pattern consists of a cup-shaped 
keratin –filled crater surrounded by an acanthotic epidermis with elongated rete 
ridges and a sparse mononuclear infiltrate20. 
Tumid Lupus Erythematosus: 
Histologically, superficial and deep dermal perivascular, interstitial and 
periappendageal lymphocytic infiltrates associated with stromal mucin deposits 
are observed21. 
Overlap syndrome- Lichen Planus / Lupus erythematosus : 
 In some cases of the overlap syndrome, the histologic features and direct 
immunofluorescence findings are more consistent with lichen planus. In others, 
the immunofluorescence testings favour lupus erythematosus22, and still in 
another subset of patients there are lesions of lichen planus that coexist, rather 
than overlap, with those of lupus erythematosus23,24 . 
Lupus Erythematosus Profundus/Panniculitis: 
Salient histologic findings include a predominantly lobular 
lymphohistiocytic infiltrate often with plasma cells occasionally forming 
germinal centers.  Vascular changes include endothelial prominence, 
thrombosis, calcification or perivascular fibrosis (“Onion Skin” appearance). 
 
IMMUNOPATHOLOGY: 
Direct immunofluorescence (DIF) testing shows the presence of 
immunoglobulins IgG, IgA, IgM and complement at the dermoepidermal 
junction in skin lesions present for 6 weeks or more, in approximately 80% of 
patients 25. They are more frequent on the face and in untreated lesions, and 
decrease after treatment with topical corticosteroid.  Homogenous, granular or 
thread patterns occurs, but the deposition is usually homogenous in older 
lesions.  Uninvolved skin is always negative, and the biopsy should always be 
from lesional skin of a well established inflammatory lesion. 
 
 
CLINICAL FEATURES: 
Lesions begin as dull red macules, papules or well defined plaques that 
develop an adherent scale and evolve with atrophy, scarring, and pigmentary 
changes.  In darker skinned individuals, lesions technically demonstrate areas of 
both hyper- and de-pigmentation.  In lighter skinned patients, the plaques may 
appear grey or have little pigment alteration.  
There is adherent scale in many cases, and when this is removed its 
undersurface shows horny plugs, which have occupied dilated pilosebaceous 
canals.  This is called ‘tin-tack’ sign or carpet tacks sign or langue au chat (cat’s 
tongue) sign26. In a study at Leeds, 14% had Raynaud’s phenomenon and 22% 
had Chilblains.  Joint pains are complained of by approximately 25% of 
patients. 
Most patients have no symptoms of systemic upset, even with widespread 
cutaneous disease. In patients with Localized Discoid Lupus Erythematosus, the 
disease is limited to the head and neck. 
In patients with Disseminated Discoid Lupus Erythematosus, discoid 
lesions are seen predominantly on the upper trunk and upper limbs, usually but 
not always in association with lesions on the head27. 
Localized Discoid Lupus Erythematosus: 
Discoid lesions are usually localised above the neck.  Favoured sites are 
the scalp, bridge of the nose, malar areas, lower lip, and ears.  The concha of the 
ear and external canal are frequently involved.  Some patients present with 
periorbital edema and erythema.  
On the scalp, most lesions begin as erythematous patches or plaques that 
evolve into white often depressed, hairless patches.  Alopecia occurs in the 
scalp lesion in approximately one-third of patients28. 
There are several clinical variants.  If hyperkeratosis is marked, warty 
lesions with a red, slightly raised edge results.  This warty type of LE is most 
commonly seen on the nose, temples, ears, and scalp, but may also occur on the 
palms and soles29. 
Non-pruritic papulonodular lesions may occur on the arms and hands, 
resembling keratocanthoma or hypertrophic Lichen planus30.  Histological 
examination of these lesions typically demonstrate a lichenoid dermatitis.  The 
lips and scalp may also demonstrate lesions that resemble lichen planus or 
lichen planopilaris.  This variant is called Verrucous Lupus Erythematosus26. 
Sometimes, the appearance may be psoriasiform31. Lesions may be 
present as reddish, well defined almost smooth plaques with little or no 
scaling31.  Sometimes these plaques may show prominent flattening in the 
center, giving rise to annular lesions.  
A pruritic chronic umbilicated papular eruption may occur on the back 
and results in acneiform hypertrophic follicular scar32. 
In 7.5% of patients, the lesions on the face resemble rosacea.  LE of this 
type presents with reddish nodular lesions on the nose, cheeks, forehead, and 
sometimes chin, and is associated with a diffuse erythema of the face and easy 
flushing.  Usually, there are no pustules as in true rosacea35. 
Another clinical type of DLE results in annular atrophic plaques on the 
face, neck, and behind the ears36. The centers of the plaques is depressed and 
sclerotic, and the lesions resemble morphea, lichen sclerosus or annular atrophic 
plaques37. 
 
Disseminated DLE: 
Disseminated DLE is less common than localized DLE38. All degrees of 
severity are encountered.  Most often the thorax and upper extremities are 
affected in addition to the head and neck.  This occurs almost always in women 
and they are usually smokers.  This variety tends to be persistant, resistant to 
therapy and associated with severe psychological upset39. 
Laboratory abnormalities such as an elevated erythrocyte sedimentation 
rate, elevated antinuclear antibodies, single stranded (ss) DNA antibodies and 
leucopenia are more common with this form of LE than with localized DLE38. 
The clinical presentation of Disseminated Discoid Lupus Erythematosus may 
vary. 
In ‘Lupus Erythematosus Telangiectoides’ reticulate telangiectasia are 
seen on the arms, legs, and back of the calves40. This clinical variant occurs in 
SLE as well as DLE41.  The appearance are characterized by a persistent blotchy 
reticulate telangiectasia, which occurs on the face, neck, ears, dorsa of the 
hands, breast, heels, and on the sides of the feet41. Healing occurs with punctate 
atrophic scarring. 
A more annular variant has been called ‘Lupus Erythematosus Gyratus 
Repens’ and consists of a migratory gyrate annular erythema with the 
histological features of LE, although lupus band test is negative42. There may be 
an underlying carcinoma. 
Rarely bullous lesions may occur43. Occasionally, one or more fingers 
may show a curious atrophic spindling, sometimes with hyperextension of the 
terminal phalanges and dystrophy of nails44. 
Arteritic lesions resembling those of Dego’s syndrome or disseminated 
atrophic blanche occasionally occur, and linear lesions following Blaschko’s 
lines have been reported45. 
Chilblain Lupus: 
Some LE patients develop red-purple patches and plaques on their toes, 
fingers, and face that are precipitated by cold, damp climates.  Such lesions are 
highly reminiscent of simple chilblains or pernio lesions47. As these lesions 
evolve, however, they take on the typical appearance of DLE lesions clinically 
and histopathologically46.  It can be precipitated by pregnancy48. Chilblains 
lupus patients often have typical DLE lesions on the face and head47.  Less 
commonly, discoid and perniotic lesions start simultaneously, and sometimes 
perniotic lesions occur alone.  A study found Ro / ss-A antibodies in the sera of 
eight out of nine Chilblain lupus patients, suggesting that these antibodies might 
be a useful clinical marker of this disorder49.  They are also either smokers, or 
have markedly abnormal peripheral circulation with low resting volume50.  
Tumid LE 
The dermal form of LE without surface/epithelial changes is known as 
Tumid LE.  Clinically affected patients display indurated papules, plaques, and 
nodules without erythema, atrophy or ulceration of the surface21.  Dermal mucin 
deposition is typical.  The lesions generally respond readily to antimalarials26. 
Mucosal DLE 
Burge and coworkers have confirmed that the prevalence of mucous 
membrane involvement in Chronic Cutaneous LE is about 25%51. While oral 
mucosa is most frequently involved, nasal, conjunctival and genital mucosal 
surfaces also can be affected51. 
Within the mouth, the buccal mucosal surfaces are most commonly 
involved, with the palate, alveolar process and tongue being sites of less 
frequent involvement51. Individual lesions begin as painless, erythematous 
patches later maturing to a chronic plaque that can present an appearance quite 
similar to that of lichen planus.  The chronic buccal-mucosal plaques have a 
sharply marginated, irregular scalloped white border with radiating white striae 
and telangiectasia51. The surface of these plaques overlying the palatal mucosa 
often has a well-defined meshwork of raised hyperkeratotic white strands that 
encircle zones of punctate erythema, which gives a “honey comb” appearance. 
The centre of older lesions can become depressed and occasionally undergo 
painful ulceration. 
Well-defined chronic DLE plaques also can appear on the vermillion 
border of the lips.  At times, DLE involvement of the lips can present as a 
diffuse chelitis, especially on the more sun exposed lower lip. Although lesions 
can appear on the tongue, this location is quite rare51.  Oral lesions may 
resemble leukoplakia52.  Erythematous lesions occur on the vulva in 5%42 or 
around the anus53. 
Eye Lesions: 
 Conjunctival DLE lesions begins as small areas of  inflammation most 
commonly affecting the palpebral conjunctivae or the margin of the eyelid.  The 
lower lid is affected more often than the upper eyelid. Palpebral lesions have 
been reported without lesions elsewhere on the face54. The eyelids are red, 
especially peripherally and are slightly infiltrated and always scaly54.  The 
lesions may itch, and are exacerbated by trauma and sunlight.  Corneal 
involvement is rare.  Superficial punctate keratopathy and stromal keratitis have 
been reported55.  Acute mucinosis of the eyelids and periorbital skin can occur56. 
Lupus Erythematosus and Erythema Multiforme-Like Syndrome (Syn. 
Rowell’s Syndrome): 
 The distinct syndrome of cutaneous LE, either discoid or systemic, 
occurring with lesions resembling erythema multiforme on the face, neck, 
hands, chest, and in the mouth was first described by Rowell in 1963 in patients 
with discoid LE, but may be seen in both subacute and systemic disease57.  
Characteristically, it lasts from a few days to over a month, but episodes may 
occur at intervals over a period of 20 years57.  The lesions are at first papular, 
but later a ring forms and the edge becomes vesicular.  Bullae, necrosis, and 
ulceration may develop if the reaction is intense, although sometimes healing 
occurs without scarring.  Patients with this syndrome also frequently have 
perniotic lesions58. 
 These patients show a characteristic pattern of serological abnormality, in 
that the speckled type of antinuclear factor is associated with  Rheumatoid 
factor and the  precipitating antibody to saline extract of human tissues (anti-
SjT)59.  When the syndrome occurs in DLE, the dermal-epidermal band test is 
positive in the discoid lesions and negative in the erythema multiforme 
lesions60. 
 
Childhood DLE: 
 DLE is uncommon in childhood62.  There appears to be no female 
preponderance, there is less photosensitivity and the frequency of progression to 
systemic disease is higher62. The other clinical features are similar to those of 
adults. 
 
Lichen planus – Lupus erythematosus Overlap Syndrome : 
 This variant is characterised by lesions that share features of lichen 
planus and lupus erythematosus. Atrophic plaques and patches with 
hypopigmentation and a livid red to blue-violet colour with telangiectasia and 
minimal scaling are characteristic. Transient bulla may develop. Classic lesions 
of lichen planus are not usually seen. Photosensitivity, pruritus and follicular 
plugging are also not common. Lesions may develop anywhere, but are most 
common on the extremities. Some patients with this overlap syndrome may 
progress to systemic lupus erythematosus. In other instances, laboratory 
evaluation may reveal only a weak-positive antinuclear antibody. This disease 
variant is characterised by a prolonged course and lack of response to treatment. 
 In some cases of the overlap syndrome, the histologic features and direct 
immunofluorescence findings are more consistent with lichen planus. In others, 
the immunofluorescence testings favour lupus erythematosus22, and still in 
another subset of patients there are lesions of lichen planus that coexist, rather 
than overlap, with those of lupus erythematosus23,24 . By direct 
immunofluorescence, the most common finding is the presence of cytoids 
staining with IgG, IgM and C3 intraepidermally or at the dermal-epidermal 
junction, as seen in classic lichen planus. Linear to granular deposition of IgM 
and C3 (as seen in lupus erythematosus, but not in lichen planus) has been 
observed occasionally. Shaggy deposition of fibrinogen at the basement 
membrane zone, typical of lichen planus, is sometimes found61. 
Lupus Erythematosus Profundus / Panniculitis: 
 Historically, referred to as Kaposi-Irgang disease63, this rare form of 
Chronic Cutaneous LE is characterized by inflammatory lesions in the lower 
dermis and subcutaneous tissue.  Approximately 70% of the patients with this 
type of Chronic Cutaneous LE also have typical DLE lesions often overlying 
the panniculitis lesions64. The term “LE profundus” has been used by some to 
arbitrarily designate those patients who have both LE panniculitis and DLE 
lesions. 
 The lesions present as deep, firm, 1-3 cm diameter nodules often with 
normal appearing overlying skin65.  The skin ultimately becomes attached to the 
firm, subcutaneous nodular lesions and is drawn inward to produce deep, 
saucerized depressions as the lesions mature65.  The head, proximal upper arms, 
chest, buttocks and thighs are the sites of predominant involvement.  Confluent 
involvement of the face can stimulate the appearance of lipoatrophy.  LE 
profundus can also present as periorbital edema66,67. 
Linear involvement of the extremities also has been observed68.  
Dystrophic calcification within older lesions of LE profundus is common and at 
times can be a prominent clinical feature of the disease requiring surgical 
excision.  In addition, LE panniculitis may produce breast nodules that can 
mimic carcinoma clinically and radiologically69. 
Associated Features: 
 Small telangiectases on the face occur in approximately 20% of the 
patients70. These dilated vessels are usually small capillaries of irregular size 
and distribution, particularly on the cheeks.  Dilated nail fold capillaries  similar 
to those seen in SLE and dermatomyositis, may be visible with naked eye70.  
More than half of the patient states that they have dry skin.  Occasionally mild 
diffuse alopecia may occur.  Alopecia areata has occurred in 10% of one series 
of DLE71. 
 Bilateral enlargement of the parotids has been reported72, 73. 
Histologically there is lymphocytic infiltration of the parotid, which is said to be 
like that of LE profundus73 .  Livedo reticularis on the legs has been reported in 
DLE74. 
 Porphyria cutanea tarda and, less commonly, variegate porphyria are 
acute intermittent porphyria may occur in patients with DLE75, 76.  The relation 
to pemphigus, myasthenia gravis and thymoma has been discussed77. 
 DLE has also been associated with chronic lymphatic leukemia, 
macroglobulinaemia78, polychondritis79, autoimmune thyroiditis80, carpal tunnel 
syndrome81, PLE82, Sheehan’s syndrome83 and erysipelas84.  Hereditary C2 
deficiency occurs in association with skin lesions resembling the discoid lesions 
of SLE85.  Hereditary deficiency of the third and of the fifth component of 
complement has also been associated with a lupus like syndrome86.  DLE has 
also occurred with C1q deficiency87. 
 
LABORATORY ABNORMALITIES IN DLE: 
 Abnormalities were found in 55% of patients88.  Anaemia, leucopenia, or 
thrombocytopenia can be found in approximately one third of the patients and 
erythrocyte sedimentation rate is raised in 20%88.  The serum globulin is raised 
in 29% of the patients88, elevation of gammaglobulin being the most common 
abnormality88.  Higher IgG levels are associated with scarring89.  Occasionally 
the Coomb’s test may be positive and cryoglobulins 90, 91 and cold agglutinins 
may be detected in the serum. 
 False positive reactions for syphilis have been reported in 26% of cases92.  
Anticardiolipin antibodies (mainly IgM) in low titers occur in approximately 
15% of patients93.  Sometimes LE cell test may be positive (1.7%).  Rheumatoid 
factor is present in approximately 17% of patients88. 
Antinuclear antibodies are found in 35%, the ‘homogenous’ type of 
antinuclear factor being twice as frequent as the ‘speckled’ type89  
Antinuclear antibodies are more common in older patients, in those who 
have had the disease for a long time and when there is extensive skin 
involvement.  They are also more common in patients with Chilblains, 
Raynaud’s phenomenon and joint pains90.  The incidents of anti-DNA 
antibodies varies from 0% to 27%91-93 .  
Antibodies to RNA occur in 42%94.  Lower titer anti-RO antibodies are 
found in 10% of the patients with DLE95.  Serum complement levels are 
occasionally reduced91.  Antibodies to the saline extracts of liver, blood vessels, 
skin, kidney, heart, spleen, leukocytes, gammaglobulin and 
deoxyribonucleoproteins have been detected by complement utilization96. The 
highest titres occur in the mildest non-scarring forms of the disease and lowest 
in the scarring type. It has been suggested that these antibodies may have a 
protective function96. 
A high incidence of antithyroid antibodies has been found in DLE, 
particularly in females97.  Gastric parietal cell cytoplasmic antibodies occur in 
13% of the patients97. 
T-cell counts are significantly lower than in controls, although B-cells are 
not reduced98.  
DIFFERENTIAL DIAGNOSIS: 
With respect to diagnosis of classical Discoid Lupus Erythematosus, 
discoid-shaped skin lesions that have erythema and hyperpigmentation at their 
active borders and depigmentation, telangiectasia and atrophy at the centers are 
very unlikely to result from dermatological disorders other than cutaneous LE. 
Polymorphous light eruption can be expressed in several clinical forms 
including succulent red plaques that occasionally can mimic earlier phases of 
evolving DLE lesions99. PLE and DLE may coexist, or PLE may precede DLE 
by many years99  . 
Sarcoidosis, Jessner’s benign-lymphocytic infiltration of the skin, 
pseudolymphoma of Spiegler-Fendt, lymphocytoma cutis, angiolymphoid 
hyperplasia with eosinophilia, lymphoma cutis, lupus vulgaris100 and  tertiary 
syphilis101 are other disorders that can clinically simulate some phases of DLE 
lesions and at times present diagnostic confusion. 
Necrobiosis lipoidica can give rise to facial lesions like DLE.  The 
rosaceous type of LE can usually be differentiated from true rosacea by the 
absence of pustules.  Granuloma faciale also can present as indolent facial 
plaques. 
Hypertrophic Discoid Lupus Erythematosus could be mistaken for 
keratoacanthoma, squamous cell carcinoma, prurigo nodularis or hypertrophic 
lichen planus102. 
The differentiated diagnosis of patients with lupus panniculitis includes 
Weber-Christian panniculitis, factitial panniculitis, pancreatic panniculitis, 
traumatic panniculitis, morphea profundus, eosinophilic fascitis, sarcoidosis, 
subcutaneous granuloma annulare and rheumatoid nodules103. Oral lichen 
planus presents the closest clinical appearance to that of oral mucosal DLE104. 
PROGNOSIS: 
Lesions of long standing with much scaling and some scarring are slower 
to remit105.  Ultimately scarring is found in 57% with scarring alopecia in 35% 
and  pigmentary abnormalities in 35% 106.  Complete remission in the course of 
years can be expected in over 50%105. 
Long duration and lack of remission are related to Raynaud’s 
phenomenon, scalp involvement and Chilblain-like lesions107. Relapses 
occurring with sunlight, cold, trauma or mental stress after months or years of 
remission are not frequent. Inspite of the chronic and relapsing nature of the 
condition, the patient usually remains  in good health. 
The risk of developing overt SLE is  approximately 6.5%107, 108.  The risk 
is higher in patients with disseminated DLE (22%) than in DLE confined to 
head and neck (1.2%). 
Squamous cell and less commonly basal cell carcinomas occasionally 
occur in scars of DLE.  An incidence of 3.3% has been noted109. 
TREATMENT: 
General measures play a large part in successful management.  Patient 
should be warned against excessive exposure to sunlight.  A sunscreen cream or 
lotion should be prescribed110. A preparation with a UVB protection factor of 
atleast 15 is required, but UVA protection is also  important. Application should 
be frequent- probably every 2-3 hours in  summer. 
Initial treatment usually includes the use of a potent topical corticosteroid 
like clobetasol propionate 0.05%, betamethasone dipropionate 0.05% or 
diflorosone diacetate 0.05%111. 
Intralesional corticosteroid injections are helpful in resistant cases112,113. 
Intralesional injections of antimalarials including chloroquine114, have been 
tried but results were not as good as with corticosteroids.  Interferon-α (IFN-α) 
has also been used intralesionally with success115.  Among other local measures, 
cryotherapy, surgical excision116, painting small lesions with trichloroacetic acid 
and local laser therapy may be helpful.  The carbondioxide laser, pulsed-dye 
and argon lasers may be valuable for telangiectatic LE117.  For patients with 
severe, extensive or scarring disease, particularly affecting the scalp, oral 
prednisolone at 0.5 mg/kg rapidly tapered over 6 weeks is quickly effective. 
One or combination of the aminoquinoline antimalarials can be effective 
for approximately 75% of patients with cutaneous LE.  Hydroxychloroquine, 
chloroquine sulphates118, mepacrine118 has helped DLE lesions.  Cigarette 
smoking reduces the efficacy of treatment with antimalarials, probably by 
modifying metabolism119.Monitoring during therapy should include taking an 
ophthalmic history, and testing reading ability with appropriate charts118. 
Other systemic drugs found useful include Acitretin, Etretinate, 
Isotretinoin, Dapsone, Methotrexate, Auronafin, Thalidomide, Clofazimine, 
Danazol, Sulfasalazine, Phenytoin, Beta-carotene, Cyclophosphomide, 
Azathioprine, Gold by intramuscular injection120-138.  Excision without grafting 
was successful in a case of verrucous LE following burn139.  
   
 
 
 
 AIM OF THE STUDY 
1. To study the incidence of Discoid Lupus Erythematosus in Government 
General Hospital, Chennai during the period between July 2006 to 
September 2008. 
2. To study the incidence of various clinical types of Discoid Lupus 
Erythematosus.  
3. To study the age and sex distribution. 
4. To study the commonest site of lesions. 
5. To study the main presenting complaints and precipitating factors. 
6. To study the relevant serological abnormalities. 
7. To study the associated disorders. 
8. To study Histopathological features in all cases and immunofluorescence 
pattern in selective cases. 
 
 
 
MATERIALS AND METHODS 
All the patients attending the outpatient department of Government 
General Hospital, Chennai during the period between July 2006 to September 
2008 were screened and patients with morphology suggestive of Discoid Lupus 
Erythematosus were enrolled in the study.  There were 51 patients who were 
clinically diagnosed as Discoid Lupus Erythematosus out of 30,056 patients 
attending Dermatology OP during the study period.  A detailed history as given 
in the proforma was elicited.  Various presenting complaints like 
photosensitivity, Raynaud’s phenomenon, joint pain, loss of hair were also 
recorded.  Biopsy was done on all patients.  All patients were subjected to 
various investigations like  Total count, differential count, hemoglobin, 
erythrocyte sedimentation rate, blood sugar, blood urea, liver function test, 
Antinuclear antibody titre, Rheumatoid factor, ‘C’ reactive proteins, and anti-
double stranded DNA antibody.  Direct Immunofluorescence was done for few 
patients.  Opinions of Rheumatologists were obtained in patients with joint pain. 
   
 
OBSERVATIONS AND RESULTS 
Incidence: 
 Of the total 30,056 patients attending Skin OP, Government General 
Hospital, Chennai during the period between July 2006 to September 2008, total 
number of patients with Discoid Lupus Erythematosus was 51. 
 Incidence of Discoid Lupus Erythematosus was 1.7 per 1000 that 
accounts to 0.17%. 
TABLE-1 
Total number of patients attending Skin OP in Govt. Gen. 
Hospital (July 2006 to September 2008) 
30,056 
Total number of patients with Discoid Lupus 
Erythematosus 
51 
Incidence of Discoid Lupus Erythematosus 0.17% 
 
 
AGE AND SEX WISE DISTRIBUTION 
Youngest age at presentation was in a 16 year old female.              Oldest age at 
presentation was in a 65 year old woman.              Incidence of DLE peaked 
between 31-50 years. DLE was more common in females (69%) than males 
(31%). The sex ratio between female and male was 2.3 : 1 in this study.         
                                           TABLE-2 
Age in years Male Female Total 
0-10 0 0 0 
11-20 0 3 3 
21-30 2 6 8 
31-40 4 11 15 
41-50 6 9 15 
51-60 4 4 8 
61-70 0 2 2 
Total 16 35 51 
 
AGE AND SEX WISE DISTRIBUTION OF LOCALIZED DLE 
Peak incidence was between 31-40 years.  Peak incidence among males was 
between 41-60 years & among females was between 31-50 years.  Localized 
DLE was more common in females (77%) than in males (23%). The sex ratio 
between female and male was 3.5 : 1 in this study.         
TABLE-3 
Age in years Male Female Total 
0-10 0 0 0 
11-20 0 3 3 
21-30 1 6 7 
31-40 2 10 12 
41-50 3 8 11 
51-60 3 3 6 
61-70 0 0 0 
Total 9 30 39 
 
AGE AND SEX WISE DISTRIBUTION OF DISSEMINATED DLE 
Incidence of Disseminated DLE peaked between 41-50 years.    Incidence of 
Disseminated DLE in males (58%) was more common than in females (42%). 
The sex ratio between female and male was 1 : 1.3 in this study.         
TABLE-4 
Age in years Male Female Total 
0-10 0 0 0 
11-20 0 0 0 
21-30 1 0 1 
31-40 2 1 3 
41-50 3 1 4 
51-60 1 1 2 
61-70 0 2 2 
Total 7 5 12 
 
CLINICAL TYPES OF DLE AND THEIR INCIDENCE 
Total number of Cases : 51 
TABLE-5 
S.No Clinical Types No. of Cases Percentage 
1 Localised DLE               
(Head & Neck) 
39 76% 
2 Disseminated DLE        
(Trunk & Extremities in 
12 24% 
addition to Head & Neck)  
 
Localized DLE was 3 times more common than disseminated DLE. 
 
 
 
 
 
LOCALIZED DLE 
Localized DLE constituted 76% of the total number of cases.  Among Localized 
DLE, the incidence of various clinical presentations are as follows: 
TABLE-6 
S. No Clinical Presentation No. of Cases Percentage 
1 Localized Discoid lesions 22 56% 
2 Localized Discoid lesions + 
Mucosal lesions 
6 15% 
3 Localized Discoid lesions + 
Follicular pits in ears 
7 18% 
4 Hypertrophic / Verrucous DLE 1         3% 
5 Mucosal lesions alone 2 5% 
6 Eye lesions 1 3% 
Total 39 76% 
 
The commonest clinical presentation of Localized DLE was Localized 
circumscribed or discoid type of lesions (56%). 
 
DISSEMINATED DLE 
Disseminated DLE constituted 24% of the total number of cases.  The incidence 
of various clinical presentations are as follows: 
TABLE-7 
S. No Clinical Presentation No. of Cases Percentage
1     Disseminated Discoid lesions 6 49% 
2 Disseminated Discoid lesions + 
Mucosal lesion 
4 33% 
3 Lupus Erythematosus - Lichen 
Planus overlap syndrome 
1 9% 
4     LE gyratus  repens 1 9% 
Total 12 24% 
 
 
 
 
MUCOSAL DLE - INCIDENCE 
Incidence of Mucosal lesions in DLE : 27%. 
Incidence of involvement of only the Mucosa  : 4%. 
Incidence of Mucosal lesions with cutaneous discoid lesions : 23%. 
Mucosal involvement in females (28%) were more common than in males 
(25%). The sex ratio between female and male was 1.1 : 1 .                
Patient with Disseminated DLE had higher incidence (42%) of mucosal lesions 
than those with localized DLE (18%). 
TABLE- 8 
Clinical Presentation Total No. of Cases 
 
Total 
Male Female 
Mucosal lesions alone 0 2 2 
Mucosal lesions along with 
Localized DLE 
1 6 7 
Mucosal lesions along with 
Disseminated DLE 
3 2 5 
Total 4 10 14 
 
 
TYPES OF MUCOSAL LESIONS 
Involvement of the lower lip was the commonest (16%) of the mucosal lesion. 
TABLE-9 
S. No Mucosal Lesion No. of Cases 
1 Erosions and crusting of Lip 8 
2 Hyperpigmented patches on the Buccal 
Mucosa 
3 
3 Erosions on the Palate 2 
4 Erosions over the Lips and Palate 1 
Total 14 
  
 
 
 
PRESENTING COMPLAINTS 
The most common presenting complaint was Burning Sensation (39%) on 
exposure to sunlight. 
TABLE-10 
S. No Presenting Complaint No. of Patients 
1 Itching 15 
2 Burning Sensation 20 
3 Loss of hair 5 
4 Cosmetic disfigurement 5 
5 Scaling 3 
6 Pain 3 
 
  
 
 
PRECIPITATING OR EXACERBATING FACTORS 
The most common exacerbating factor was sunlight (57%).  
 
TABLE-11 
S. No Precipitating or Exacerbating 
Factor 
No. of Cases 
1 Sunlight 29 
2 Trauma  1 
3 Mental Stress 2 
4 Burns 1 
5 Pregnancy 1 
6 Drugs 2 
7 Premenstrual Flare 1 
 
 
 
OCCUPATION OF THE PATIENT 
     31% of the patients were agriculture labourers. 
      10% of the patients were watchmen.            
    TABLE-12 
OCCUPATION MALE FEMALE PERCENTAGE 
Agriculture  4 12 31 
Housewife  20 39 
Watchman 5  10 
Shopkeeper 2  4 
Student  1 2 
Teacher 1 1 2 
Driver   2 
Tailor 1 1 2 
Mason 1  2 
Office clerk 1  2 
Plumber 1  2 
Photographer 1  2 
Total 16 35  
 
 
 
SITE OF INVOLVEMENT 
LOCALISED DLE 
Total number of cases : 39 
Most common site involved in Localized DLE - scalp (38%)  
TABLE-13 
S.No Site No. of Cases 
1. Scalp 15 
2. Face 4 
3. Lips 2 
4. Ears 3 
5. Multiple Sites (Scalp, 
Face, Ears, Lips) 
15 
 
DISSEMINATED DLE 
Trunk was involved in 92% of Disseminated DLE Cases along with lesions on 
the head. 
Trunk alone was involved in a single case. 
TABLE-14 
S.No. Site No. of cases 
1. Head, Trunk & Upper 
limbs 
2 
2. Head, Trunk ,Upper & 2 
lower limbs 
3. Head & Trunk 6 
4. Head &  Upper limb 1 
5. Trunk alone 1 
 
RAYNAUD’S PHENOMENON: 
No. of cases with H/o Raynaud’s phenomenon  : 3 
Percentage of cases with Raynaud’s phenomenon   : 6% 
TABLE-15 
 
Type 
  
Raynaud’s 
phenomenon+ 
 
Total no. of 
cases 
 
% 
Localized DLE 1 39 2.5 % 
Disseminated DLE 2 12 17 % 
Total 3 51 6 % 
 
JOINT PAIN: 
12% of Cases (6) had complaints of joint pain. Joint pain was more common in 
Disseminated DLE than in Localized DLE. 
TABLE-16 
Type No. of Cases Total no. of % 
with joint pain cases 
Localized DLE 2 39 5 % 
Disseminated DLE 4 12 33 % 
Total 6 51 12 % 
ASSOCIATED CONDITIONS 
TABLE - 17 
Associated Conditions No. of Patients 
Polymorphic Light Eruption 1 
Diffuse Hair Loss 1 
Urticaria 1 
Prurigo nodularis 1 
Macular Amyloid 1 
Hypothyroidism 2 
Diabetes Mellitus 2 
Hypertension 1 
Pterigium of Eye 1 
 
LABORATORY ABNORMALITIES IN  DLE 
ANAEMIA:  
Percentage of patients with anaemia were found to be 25% 
TABLE – 18 
Type No. of Patients 
with anaemia 
Total no. of 
Pts 
% 
Localized DLE  10 39 26 % 
Disseminated DLE  3 12 25% 
Total  13 51 25% 
 
ERYTHROCYTE SEDIMENTATION RATE (ESR): 
Percentage of patients with raised ESR was 57% 
TABLE – 19 
ESR >20mm/hr No. of Patients 
Total no. of patients investigated 51 
Total no. of patients with raised ESR 29 
Percentage of patients with raised ESR 57% 
OTHER PARAMETERS: 
• Total Leukocyte count, platelet counts were within normal limits in all 
patients. 
• No abnormality was detected in Renal and Liver Function parameters. 
• Serum proteins were normal in all patients. 
ANTINUCLEAR ANTIBODY POSITIVITY 
Percentage of patients with ANA positivity was found to be 29% 
TABLE – 20 
Types of DLE ANA Positivity Total No. of Cases Percentage 
Localized DLE 10 39 26% 
Disseminated DLE 5 12 42% 
Total 15 51 29% 
 
RHEUMATOID FACTOR 
Percentage of Rheumatoid Factor positivity was found to be 33%   
TABLE – 21 
Type RF Positive Total No. of Patients Percentage 
Localized DLE 11 39 28% 
Disseminated DLE 6 12 50% 
Total 17 51 33% 
 
C-REACTIVE PROTEIN (CRP) 
Percentage of CRP Positivity was found to be 33% 
TABLE – 22 
Type CRP Positive Total No. of Patients Percentage 
Localized DLE 9 39 23% 
Disseminated DLE 8 12 67% 
Total 17 51 33% 
 
ANTI – DOUBLE STRANDED DNA ANTIBODY was found to be negative 
in all patients. 
NEOPLASTIC CHANGES IN DLE 
Only one case presented with malignant change.  
One case presented with Squamous Cell Carcinoma complicating Lupus 
Erythematosus – Lichen Planus overlap Syndrome. 
Incidence of Malignancy in DLE  : 2% 
HISTOPATHOLOGY : 
 Skin biopsy was done in all the cases. Histopathological study showed 
compatibility with the features of DLE in all cases, except one. One case 
showed features suggestive of Lichen planus. Biopsy of the verrucous growth 
from the lesional skin on the right elbow in this case showed features of well 
differentiated squamous cell carcinoma. Another case showed features 
suggestive of Verrucous DLE.  
DIRECT IMMUNOFLUORESCENCE : 
 DIF was done in a few cases . The biopsy was taken from the lesional 
skin, exposed nonlesional skin and unexposed non-lesional skin. Most of the 
cases showed moderately strong homogenous IgG, IgM, IgA and C3 at the 
basement membrane zone band in the lesional skin and negative in the 
uninvolved skin, features suggestive of Discoid Lupus Erythematosus. One case 
showed Discontinuous ragged fibrinogen band in the basement membrane zone 
and IgG, IgM and C3 colloid bodies in the lesional skin. These features were 
suggestive of Lichen planus. 
  
 
 
 
 
 
 
 
 
 
 
  DISCUSSION 
In this study, among the total 30,056 patients attending Skin OP, 
Government General Hospital, Chennai during the period between July 2006 to 
September 2008, total number of patients with DLE was 51. The incidence of 
DLE was found to be 1.7 per 1000 ( Tab.1 ). A study by G. H. Findlay and J. G. 
H. Lups of 191 cases, the incidence was found to be 0.07 per 1000 140 . 
  In this study, the youngest age at presentation was 16 years and the 
oldest age  was 65 years. Incidence of  DLE peaked between 31 – 50 years 
(Tab.5). This was similar to the study by Damm J and Sonnischsen N where the 
peak age of onset was 4th decade in female and slightly later in males9 . 
 The sex ratio between female and male was 2.3 : 1 in this study (Tab.2). 
In the study by Damm J and Sonnischsen N, the sex ratio was   2 : 1 . The  
female to male ratio for Localised DLE in this study was   3.5 : 1 (Tab.3) as 
compared to 3 : 1 in the study conducted by  Tebbe R and Orfanos141. The 
female to male ratio for disseminated DLE was 1 : 1.3 in this study (Tab.4) as 
compared to 13 : 1 in the study conducted by Tebbe R and Orfanos141 . There 
was no incidence of familial cases in this study. In the study by G. H. Findlay 
and J. G. H. Lups one case of familial occurrence was found in a series of 191 
cases140  . Sonnichsen et al in east berlin have had similar experience. They 
found only three familial cases in a total of 1,100 affected cases140 . 
 Percentage of Localised and Disseminated DLE was 76% and 26% 
respectively in this study (Tab.5) , where as in a study by Tebbe R and Orfanos 
of  97 patients the percentage of localized and disseminated DLE was 40% and 
60% respectively141 . 
In this study, the percentage of cases with mucosal lesions was 27% 
(Tab.8) similar to the study conducted by Thai Helena and Nelson Guimaraes 
Proenca142 .   
 Mucosal involvement was seen 28% of females compared to 25% in male 
patients (Tab.8). Patients with Disseminated DLE had higher incidence (42%) 
of mucosal lesions than those with localized DLE (18%) (Tab-8). 
Involvement of the lips was the commonest (16%) of the mucosal lesion 
(Tab-9) in this study. In a study by  Thai Helena and Nelson   Guimaraes 
Proenca , lips were the commonest site (13%) of mucosal lesion142 . 
 The most common presenting complaint was burning sensation (39%) on 
exposure to sunlight, followed by itching (29%) in this study(Tab-10). In a 
study by Thai Helena and Nelson Guimaraes Proenca , itch and aggravation 
following sun exposure (59%) was the commonest complaint, followed by 
pruritus(42%)142 . 
 The most common exacerbating factor was sunlight (57%) in this study 
followed by mental stress (0.3%), drugs (0.3%), trauma (0.1), burns (0.1%), 
pregnancy (0.1%) and premenstrual flare (0.1%) (Tab- 11). In a study at Leeds, 
the most common precipitating factor was mental stress (12%), followed by 
trauma (11%), sunburn (5%), infection (3%), exposure to cold (2%) and 
pregnancy (1%)143 . In this study,  31% of the patients were agriculture cooly 
and 10% of the patients were watchman by occupation(Tab.12). Both 
agricultural labourers and watchman have more exposure to sunlight, which is 
one of the precipitating and exacerbating factor of DLE. 
  In this study, Scalp was involved in 38% of the localized DLE cases 
(Tab-13) similar to the study by Thai Helena and Nelson Guimaraes Proenca 
where scalp was involved in 31.7% of cases142  . 
 Trunk was involved in 92% of Disseminated DLE cases. This study also 
showed that 0.1% of the cases had lesions exclusively in the trunk (Tab-14) 
whereas in the study by Thai Helena and Nelson Guimaraes Proenca, 0.3% of 
the cases had lesions exclusively in areas other than cephalic segment142 . Trunk 
was involved in 21% of DLE cases in this study (Tab-14) compared to 32% in 
the study by  Thai Helena and Nelson Guimaraes Proenca142 . 
 Raynaud’s phenomenon was present in 6% of cases in this study (Tab-15) 
compared to 14% in the study at Leeds of 120 patients144 . 
 12% of cases had joint pain in this study (Tab-16) compared to 24% in 
this study by Thai Helena and Nelson Guimaraes Proenca142 . 
 Associated conditions in this study includes polymorphic light eruption, 
diffuse hair loss, urticaria, prurigo nodularis, macular atrophy, macular amyloid, 
hypothyroidism, diabetes mellitus, hypertension and pterigium of the eye (Tab-
17). Wojnarowska F reported simultaneous occurrence of DLE and 
polymorphic light eruption82 .Mild diffuse hair loss has been reported by Werth 
VP, White WL and Sanchez MR71 . Autoimmune thyroiditis has been reported 
by Van der meer-Rosen CH, Maes EPJ and Faber WR80 .   
 20% of patients in this study were known smokers. An association 
between DLE and smoking has been reported146 . Disseminated DLE is reported 
to occur more commonly in women who are cigarette smokers39.  A higher 
prevalence was noted in DLE cases (84.2%) than control (33.5%) in a study146. 
 Skin biopsy was done in all the cases. All cases showed features 
suggestive of Discoid Lupus Erythematosus. One case showed features 
suggestive of Lichen planus. Biopsy of the verrucous growth from the lesional 
skin on the right elbow in this case showed features of well differentiated 
squamous cell carcinoma. Another case showed features suggestive of 
Verrucous DLE.  
 DIF was done in a few cases. Most of the cases showed moderately 
strong homogenous IgG, IgM, IgA and C3 at the basement membrane zone 
band in the lesional skin and negative findings in the uninvolved skin, features 
suggestive of Discoid Lupus Erythematosus. One case showed Discontinuous 
ragged fibrinogen band in the basement membrane zone and IgG, IgM and C3 
colloid bodies in the lesional skin. These features were suggestive of Lichen 
planus. 
One of the case showed clinical features suggestive of Disseminated 
Discoid Lupus Erythematosus. But the histological and direct 
immunofluorescence findings were consistent with Lichen planus. Hence a final 
diagnosis of Lupus erythematosus-Lichen planus overlap syndrome  was made. 
This case had a verrucous growth developing from the skin lesion on the right 
elbow which was histologically a well differentiated squamous cell carcinoma. 
 Laboratory investigations showed anaemia in 25% and raised ESR in 
57% of patients (Tab-18,19). A study by Rowell NR found anaemia, leucopenia 
or thrombocytopenia in approximately one – third of patients and ESR was 
raised in 20% of patients88 . Total leucocyte count, platelet counts were within 
normal limits in all patients in this study. Serum proteins were normal in all the 
patients in this study. 
 ANA positivity was 29% in this study (Tab-20), whereas in the study by 
Rowell NR 35% of patients showed ANA positivity88 . In this study, percentage 
of ANA positivity in localized DLE was 26% compared to 42% in disseminated 
DLE. 
 Rheumatoid factor was positive in 33% of patients (Tab-21), whereas in 
the study by Rowell NR, 17% of patients were positive for rheumatoid factor88 . 
C reactive protein positivity was found in 33% of patients in this study (Tab-
22). Anti-ds-DNA antibody was negative in all patients in this study similar to 
the study by Kulick KB, Provost TT and Reichlin M92 . In another study by 
Davis P, Atkin B and Hughes GRV anti-DNA antibodies were found in 27% of 
the cases93 . 
 Malignant change was found in only one case (2%) in this study. In a 
study by Millard LG and Barker DJ, an incidence of 3.3% was noted in a series 
of 120 white patients109 . 
 
 
 
 
 
 
 
 
 
 
 
 
     CONCLUSION 
• The incidence of Discoid lupus erythematosus during the period from 
July 2006 to September 2008 was 1.7 per 1000. 
• The incidence of Localised and Disseminated discoid lupus 
erythematosus were as follows 
Localised DLE - 76%      
Disseminated DLE – 24% 
• The most common clinical presentation of localized DLE was        
localised circumscribed  lesions (59%). 
• The maximum number of patients were in the age group of 31 – 50 years. 
• The female to male sex ratio was 2.3 : 1 
• No familial cases were seen. 
• Peak incidence of localised DLE was between 31 to 40 years. Peak 
incidence of disseminated DLE was between 41 to 50 years. 
• Localised DLE was more common in females (77%) than males (23%) 
• Disseminated DLE was more common in males (58%) than females 
(42%). 
• Mucosal lesions were found in 27% of the patients. Patients with 
disseminated DLE had higher incidence of mucosal lesions (42%) than 
those with localised DLE (18%). 
• Mucosal involvement was more common in female patients (28%) than in 
males (25%). 
• Involvement of the lower lip was the commonest of the mucosal lesions. 
• The most common presenting complaint was burning sensation (39%) on 
exposure to sunlight. The most common exacerbating factor was sunlight 
(57%). 
• Scalp (38%) was the most common site involved in localized DLE. Trunk 
was involved in 92% of disseminated DLE patients. 
• Raynaud’s phenomenon was present in 6% of the patients. 12% of 
patients had complaints of joint pain. 
• Laboratory investigations showed anaemia in 25% and raised ESR in 
57% of the patients. 
• ANA was found in 29% of the patients. ANA positivity was more 
common in disseminated DLE(42%) than in localized DLE (26%). 
•  Anti-double stranded DNA was negative in all the patients. 
•  Rheumatoid factor was positive in 33% of the patients. C reactive 
proteins was positive in 33% of the patients. 
• Histopathological study showed compatibility with the features of DLE in 
all cases, except one. One case showed features of lichen planus. Another 
case showed features of Verrucous DLE. 
• Direct immunofluorescence study showed moderately strong 
homogenous IgG, IgM, IgA and C3 at the basement membrane zone band 
in the lesional skin and negative findings in the uninvolved skin, features 
suggestive of Discoid Lupus Erythematosus in most of the cases. One 
case showed discontinuous ragged fibrinogen band in the basement 
membrane zone and IgG, IgM and C3 colloid bodies in the lesional skin. 
These features were suggestive of Lichen planus. 
• Neoplastic change was noted in 2% of the cases. 
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PROFORMA 
Case no.    O.P No. 
Complaints : 
Duration :    Onset : 
SITE 
Head : Scalp , Face , Ears , Eyes , Lips , Oral mucosa, nasal mucosa  
Trunk : Chest , Back , Abdomen, Genitalia 
Limbs : Upper limbs / Lower limbs , Palms , Soles 
ASSOCIATED COMPLAINTS 
Photosensitivity:  Itching:  Pain:  Scaling: Raynaud’s 
Phenomenon:  Joint Pain: 
PRECIPITATING FACTORS 
Sunlight: Drugs:   Dapsone, Isoniazid, Griseofulvin, Penicillamine 
Trauma: Radiation exposure: Mental stress: 
Exposure to cold:  Pregnancy:  Premenstrual deterioration: 
 
HISTORY RELATED TO SYSTEMIC INVOLVEMENT: 
 Constitutional symptoms, Arthralgia, Chest pain, Palpitation, Dyspnea, 
Dysphagia, Vomiting,  Abdominal pain, Epilepsy, Psychosis,  Oliguria, Pedal 
edema.  
PAST HISTORY: 
PERSONAL HISTORY: Smoking, Alcohol 
MENSTRUAL HISTORY (In Female): Any Premenstrual exacerbation 
OCCUPATIONAL HISTORY: 
TREATMENT HISTORY: 
GENERAL EXAMINATION: 
Anaemia:  Jaundice:  Cyanosis: Pedal edema:    Lymphadenopathy: 
Clubbing: 
Vital signs:  Pulse rate:   BP:  TEMP: RR: 
SYSTEMIC EXAMINATION: 
C.V.S:  R.S:  C.N.S:  PER/ABD: 
DERMATOLOGICAL EXAMINATION: 
MORPHOLOGY:   Plaque/Patch: Erythema:      Depigmentation: 
Atrophy: Scaling: Hyperpigmentation: Scarring: 
Carpet Tacks Sign: 
SITE: 
LOCALISED: 
Scalp: Face:  Ears:  Neck:   
Retroauricular: `Oral mucosa:  Nasal mucosa: Lips:    Eyes: 
DISSEMINATED: 
Chest: Back:  Arms: Forearms: Dorsum of hand: 
Palms: Thighs: Legs:  Dorsum of Foot:  Soles: 
Genitalia:  
Nails: 
Hair: Alopecia 
INVESTIGATION: 
Urine: albumin, sugar, deposits. 
Hb:   Total count: Differential count:  ESR: 
Platelet count: 
Renal Function Test:     Bd Sugar, Urea, Serum Creatinine 
Liver Function Test:    Serum Bilurubin,Total Proteins, SGOT, SGPT, Alkaline 
phosphatase. 
ANA Titre: 
Rheumatoid factor:  C-reactive protein: 
Histopathological Examination:    
Direct immunofluorescence: 
Rheumatology opinion: 
 
 
 
 
 
 
 
 
 
 
KEY TO MASTER CHART 
M   - Male 
F   - Female 
Ppt   - Precipitating factor 
Aggr   - Aggravating factor 
Jt   - Joint 
Clin   - Clinical 
Asst   - Associated 
Hb   - Haemoglobin 
TC   - Total count 
ESR   - Erythrocyte sedimentation rate 
RFT   - Renal function test 
LFT   - Liver function test 
RF   - Rheumatoid factor 
CRP   - C reactive protein 
ANA   - Antinuclear antibody 
ds-DNA  - Double stranded DNA 
S   - Smoking 
A   - Alcohol 
Yrs   - Years  
Agri   - Agriculture 
H.W   - Housewife 
W.M   - Watchman 
S.K   - Shopkeeper 
Stud   - Student 
Driv   - Driver 
 
 
 
 
